Le Lézard
Classified in: Health
Subjects: NPT, POL, AVO, MAT

Trump Administration's Ban on Flavored E-Cigarettes Does More Harm


PLATTSBURGH, N.Y., Sept. 11, 2019 /PRNewswire/ -- Today, following the announcement by Donald Trump that his administration will be supporting action from the Food and Drug Administration "to clear the market of flavored e-cigarettes," Alex Clark, CEO of The Consumer Advocates for Smoke-free Alternatives Association (CASAA) issued the following statement:

The Consumer Advocates for Smoke-free Alternatives Association (casaa.org). (PRNewsFoto/Consumer Advocates for Smoke...)

"Removing from the market and prohibiting the sale of nicotine vapor products in flavors other than tobacco will inevitably lead to the creation of a massive, unregulated underground market that exposes consumers to dangerous and unnecessary risks. Flavored vapor products were developed by consumers who wanted better quality and more effective alternatives to smoking. That grassroots entrepreneurship and innovation is at the core of the vaping community and the industry it supports.

"Flavors play a critical role in helping people transition away from combustible tobacco products. Prohibiting them means that millions of people who vape are at higher risk of returning to smoking or seeking products through other means. Meanwhile, young people will still try risky behaviors--including cannabis, alcohol, sex, texting while driving, and nicotine products. By destroying the legal, regulated retail environment, the Trump Administration will be sending millions of consumers, regardless of age, to a marketplace in the shadows--away from the oversight of regulators, law enforcement, and parents.

"If we have learned anything from the recent outbreak of lung illnesses attributed broadly to vaping, it's that products made and sold in an underground market are inherently risky. When people are injured or killed as a result of using products purchased from unlicensed dealers, it is irresponsible to move regulated products to those markets. Future incidents like the ones we've experienced this summer are avoidable, but only if officials take bold action to provide a safer and well-regulated marketplace for products that people are going to consume."

The Consumer Advocates for Smoke-free Alternatives Association (CASAA) is a non-profit 501(c)(4) organization with an all-volunteer board and a grassroots membership of more than 250,000 active members from all walks of life. CASAA is dedicated to ensuring the availability of reduced harm alternatives to smoking and to provide people who smoke and the public with honest information about those products. CASAA will continue its efforts in advocating for more reasonable, ethical, and sensible regulations.

SOURCE Consumer Advocates for Smoke-free Alternatives Association


These press releases may also interest you

at 10:19
Revvity's EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits...

at 10:17
Fx Chocolate®, a Designs for Health brand that provides functional amounts of high-quality supplements in handcrafted chocolate, today announced the launch of its Yes Whey!!!tm chocolate supplement bar. Yes Whey!!!tm harnesses 15 grams of...

at 10:16
Varian, a Siemens Healthineers Company, announces its collaboration with BaraSeen Medical Company to introduce the first Halcyon system in Saudi Arabia - with its hallmark sustainability features - at BaraSeen's initial specialized standalone Batik-X...

at 10:15
From the childhood dream of becoming a veterinarian and saving the lives of pets, to today's realities of practicing veterinary medicine, the deep commitment veterinarians feel for their calling remains unchanged. However, certain factors make that...

at 10:12
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

at 10:02
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....



News published on and distributed by: